adMare
News

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Pathway to Cures Invests in SeraGene Therapeutics

With the U.S. on uncertain footing, Quebec must stand strong in life sciences

Article available in French only

Domain Therapeutics Doses First Patients in Phase I/II Trial of DT-7012 Targeting CCR8 in Solid Tumors

Epitopea Strengthens Scientific Advisory Board with Appointment of Four World Renowned Experts in Cancer Immunology and Immunotherapy

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

adMare Executive Institute Opens Applications for Eighth Cohort

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

New adMare Institute Report Examines Capital Flows in Canadian Life Sciences and the Urgent Need to Capture Domestic Economic Value